
About OXB
OXB is a publicly listed company based in Oxford (United Kingdom) founded in 1995 by Neill Mackenzie. Gene therapies for multiple diseases are developed via lentiviral systems. It operates on a Managed Services and Professional Services model. The company has 861 employees. OXB has completed 4 acquisitions, including ABL, ABL Europe and Homology Medicines. Its chief executive, as recorded, is Tim Kelly. Its website oxb.com draws about 21 thousand monthly visits. OXB offers products and services including LentiVectorâ„¢ Platform, inAAVateâ„¢ Platform, and CDMO Services. Its focus areas include Biotechnology and Cell and Gene Therapy. Its legal entity is Oxford Biomedica PLC. Its competitors include Ori Biotech and eXmoor; 2 of its 2 listed competitors have raised funding.
Company details
OXB is established as a global leader in cell and gene therapy contract development and manufacturing (CDMO), with over 30 years of expertise in viral vectors. Services are provided to innovative pharmaceutical and biotechnology companies, covering lentivirus, AAV, adenovirus, and other vector types. End-to-end capabilities are offered, from early-stage development to commercialization, supported by robust quality systems and regulatory knowledge. Operations span multiple sectors within healthcare, focusing on enabling life-changing therapies for patients worldwide through advanced manufacturing and development solutions.
- Annual Revenue$227.22 M (USD)31.01as on Dec 31, 2025
- Net Profit-$40.57 M (USD)30.24as on Dec 31, 2025
- EBITDA-$12.28 M (USD)60.84as on Dec 31, 2025
- Latest Funding Round$81.34M (USD), Post-IPO
Aug 2025
- InvestorsBriarwood Chase Management
& 1 more
- Employee Count861
- Investments & AcquisitionsABL
& 3 more
Products & Services of OXB
OXB offers a comprehensive portfolio of products and services, including LentiVector™ Platform, inAAVate™ Platform, and CDMO Services.
Innovative lentiviral gene delivery technology is commercially approved.
Proven AAV vector development ensures high-quality clinical products.
End-to-end viral vector manufacturing supports cell therapy clients.
Apps and channels of OXB
its YouTube channel OXB has 153 subscribers and 6 videos.
Videos from OXB
The most watched videos on OXB's YouTube channel, OXB (153 subscribers). Click a video to play it here.
More on OXB.
Funding Insights of OXB
- Total Rounds 4
- Last Round Post-IPO — $81.34M
- Investors Count 2
All 4 funding rounds of OXB with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2025 | $81.34M | Post-IPO | – | – | – |
| Jan 2025 | Post-IPO | – | – | ||
| Sep 2021 | $68.33M | Post-IPO | – | – | – |
| Apr 2019 | Unspecified | – | – |
2 investors in total: 2 institutional.
Investors in OXB
OXB has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Briarwood Chase Management and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Briarwood Chase Management is focused on long-term global investments. | briarwoodcap.com | New York, United States |
Investor details for OXB
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OXB
185 people are tracked at OXB (63 in leadership, 6 in board & advisors, 116 in team); the tracked headcount is 861.
| Name | Role | Group |
|---|---|---|
Neill Mackenzie | Founder | Leadership |
Tim Kelly | CEO | Leadership |
Heather Preston | Non Executive Director & Board Member | Leadership |
Frank Mathias | CEO | Leadership |
Kyriacos Mitrophanous | Chief Scientific Officer | Leadership |
Sandrine Lopes | Senior Director, Head Of Business Development EMEA | Leadership |
Aziz Kagdi Mba, Cmgr Fcmi | Operations Programme Director | Leadership |
Fiona Forsyth (née Sandeman) | Director Clinical Operations | Leadership |
Aurélie Charpentier | Director Of Business Development | Leadership |
Lucinda Crabtree | Chief Financial Officer | Leadership |
Yvonne Sun | Director Of Quality Assurance Operations (gene Therapy Aav) | Leadership |
Simon Simpkins | Vp, Head Of Analytical Development And QC | Leadership |
Lisa James | Chief People Officer | Leadership |
Sébastien Ribault | Chief Commercial Officer | Leadership |
Colin Grugeon | Recruitment Business Partner | Leadership |
Thierry Cournez | Chief Operating Officer | Leadership |
Mark Caswell | Site Head of US Operations | Leadership |
Sharmilee Patel | Head Of Business Development, US EC | Leadership |
Satpal Griffiths | Senior Director, Analytical Services | Leadership |
Julie Copperthwaite | Head Of Group HR Operations | Leadership |
165 more people are available in the full profile.
Complete people profiles for OXB
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of OXB
OXB is a publicly listed company on the LSE with ticker symbol OXB in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Nov 2008
- Listed onOTCMKTS: OXBDF
- Listed entityOxford BioMedica plc
- Exchange sectorHealth technology
- ISINGB00BDFBVT43
- Share price514.00 GBX · 2026-10-14
- Market capitalisation622,032,335.00 GBX
- EPS (diluted, trailing year)-0.34 GBX
- Volume (last session)1,504
Financials of OXB
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 168.7M GBP | -30.1M GBP | -9.1M GBP |
| 2024 | 128.8M GBP | -43.2M GBP | -23.3M GBP |
| 2023 | 89.5M GBP | -157.5M GBP | -60.1M GBP |
| 2022 | 140.0M GBP | -39.2M GBP | -28.3M GBP |
| 2021 | 142.8M GBP | 19.0M GBP | 32.4M GBP |
Detailed financial statements for OXB
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OXB
OXB has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include ABL, ABL Europe and Homology Medicines.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Preclinical development services are provided by ABL to biotechnology clients. | abl-europe.com | Rockville, United States | 1961 | Dec 2023 | •••• | |
Contract research and manufacturing for biologics and vaccines are provided. | ablinc.com | Rockville, United States | 1961 | Sep 2023 | $15.8M | |
Developer of gene therapies for rare genetic diseases | homologymedicines.com | Lexington, United States | 2015 | Jan 2022 | •••• | |
Biotechnology products are developed to enhance immune responses against diseases. | oxti.com | Fairfield, United States | 2004 | Mar 2007 | $30.91M |
Complete acquisition details for OXB
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of OXB
8 dated milestones of OXB across 30 years, from founding to its latest funding, stage changes and deals.
- Founded OXB is founded.
- Acquisition Acquires Oxti.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Acquisition Acquires Homology Medicines.
- Acquisition Acquires ABL.
- Acquisition Acquires ABL Europe.
- Funding Latest funding round, Post-IPO, of $81.3M.
Competitors of OXB
OXB has 2 listed competitors in our database, 2 of them funded. They include Ori Biotech and eXmoor.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| oribiotech.com | 2015 | London, United Kingdom | $281.12M | 52 | Software development services are provided for the biopharma sector. | |
| exmoorpharma.com | 2004 | Bristol, United Kingdom | $51.75M | Cell and gene therapeutic services are provided to biopharmaceutical firms. |
Detailed competitors of OXB
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OXB
The website of OXB (oxb.com) receives about 21.1K visits a month and ranks #1,726,571 among all websites worldwide, #2,341 in Biotechnology and Pharmaceuticals.
- Monthly visits21.1K
▲ 56.7% vs previous month
- Unique visitors6.1K
per month
- Global rank#1,726,571
among all websites
- Category rank#2,341
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit2.0
- Average visit58 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with OXB. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharmaventures.com | 100% | View details | |||
accord-healthcare.com | accord-healthcare.com | 97% | #1,035,209 | – | |
| evoxtherapeutics.com | 95% | 9K | #2,464,657 | View details | |
pipelinereview.com | pipelinereview.com | 94% | – | ||
insights.bio | insights.bio | 90% | #986,365 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for OXB
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oxb
Complete news archive for OXB
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OXB
OXB was founded in 1995 and raised its 1st funding round 24 years after it was founded.
OXB is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Tim Kelly is the CEO of OXB, as recorded in our data.
OXB has 861 employees.
Annual revenue of OXB is $227.22M as on Dec 31, 2025.
OXB is established as a global leader in cell and gene therapy contract development and manufacturing (CDMO), with over 30 years of expertise in viral vectors. Services are provided to innovative pharmaceutical and biotechnology companies, covering lentivirus, AAV, adenovirus, and other vector types. End-to-end capabilities are offered, from early-stage development to commercialization, supported by robust quality systems and regulatory knowledge. Operations span multiple sectors within healthcare, focusing on enabling life-changing therapies for patients worldwide through advanced manufacturing and development solutions.
OXB's top competitors include Ori Biotech and eXmoor.
OXB offers LentiVectorâ„¢ Platform, inAAVateâ„¢ Platform, and CDMO Services.
Yes, OXB is publicly traded on LSE under the ticker symbol OXB.
OXB has made 4 acquisitions, including ABL, ABL Europe, and Homology Medicines.
OXB has 2 investors. Key investors include Briarwood Chase Management, and Novo Holdings.
OXB operates through Oxford Biomedica Plc.
